BioSpace News Archive

Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023, at 2:35 p.m. EDT.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced it will host a conference call on Thursday March 16 at 08.30 a.m. Eastern Time to discuss its financial and operating results for the full fiscal year 2022, in addition to providing a business update.

Semler Scientific, Inc. announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, after the close of U.S. financial markets on Tuesday, March 21, 2023.

Agilent Technologies Inc. announced it has partnered with Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, to incorporate their NanoZoomer range including the S360MD Slide scanner system into the Agilent end-to-end digital pathology solution.

The Executive Management Board of Medigene AG, an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, adjusted financial guidance for fiscal year 2022.

Further to the announcement made on 8 March 2023 providing notice of a general meeting of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM and form of proxy, the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:

Omeros Corporation, in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank.

New research in the March 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights how the lack of genomic research for people with African ancestry, particularly those from the Sub-Saharan region, is hampering efforts to reduce disparities for people with cancer.

Kiromic BioPharma, Inc. announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time , March 10, 2023.

Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced its financial results for the three and 12 months ended December 31, 2022, and provided a clinical and business update.